TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and the release of a short-seller report. Data demonstrates that the recent ...

TransMedics reported extremely strong Q1 results, alleviating concerns from a weak Q3 2024 and a short attack in January. The company continues to expand its logistics capabilities and should see a ...

The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...

TransMedics Group, Inc. TMDX investors are encountering some short-term losses from the stock of late. Shares of the Andover, MA-based commercial-stage medical technology company providing organ ...

ANDOVER, Mass., Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

TransMedics Group Inc. (NASDAQ:TMDX) is one of the 10 best growth stocks to buy according to billionaires. The stock has had a tremendous year so far, with share price gains of 129%, leading other ...

TransMedics announced today that it entered into a strategic collaboration with Mercedes-Benz Group AG for organ transplant ...

TransMedics continues to lock in its status as the leader in organ transplant technology. Josh Kohn-Lindquist is a contributing Motley Fool stock market analyst covering consumer goods, industrials, ...

Back in Robin Cook's 1977 novel Coma—and Michael Crichton's 1978 film adaptation—healthy patients are deliberately pushed into irreversible comas so their organs can be harvested and sold on the black ...

Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence. TransMedics reported ...